These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management. Boden WE Curr Opin Cardiol; 2003 Jul; 18(4):278-85. PubMed ID: 12858126 [TBL] [Abstract][Full Text] [Related]
3. High-density lipoprotein cholesterol and coronary heart disease. Young CE; Karas RH; Kuvin JT Cardiol Rev; 2004; 12(2):107-19. PubMed ID: 14766026 [TBL] [Abstract][Full Text] [Related]
4. HDL-C: role as a risk modifier. Barter P Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280 [TBL] [Abstract][Full Text] [Related]
5. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial. Boden WE Am J Cardiol; 2000 Dec; 86(12A):19L-22L. PubMed ID: 11374850 [TBL] [Abstract][Full Text] [Related]
6. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Nesto RW Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526 [TBL] [Abstract][Full Text] [Related]
7. Raising low levels of high-density lipoprotein cholesterol is an important target of therapy. Boden WE; Pearson TA Am J Cardiol; 2000 Mar; 85(5):645-50, A10. PubMed ID: 11078282 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial. Nyman JA; Martinson MS; Nelson D; Nugent S; Collins D; Wittes J; Fye CL; Wilt TJ; Robins SJ; Bloomfield Rubins H; Arch Intern Med; 2002 Jan; 162(2):177-82. PubMed ID: 11802751 [TBL] [Abstract][Full Text] [Related]
9. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
10. Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention? Wierzbicki AS Curr Med Res Opin; 2005 Feb; 21(2):299-306. PubMed ID: 15802001 [TBL] [Abstract][Full Text] [Related]
11. Managing the risk of atherosclerosis: the role of high-density lipoprotein. Libby P Am J Cardiol; 2001 Dec; 88(12A):3N-8N. PubMed ID: 11788123 [TBL] [Abstract][Full Text] [Related]
13. High-density lipoprotein and coronary heart disease: current and future therapies. Natarajan P; Ray KK; Cannon CP J Am Coll Cardiol; 2010 Mar; 55(13):1283-99. PubMed ID: 20338488 [TBL] [Abstract][Full Text] [Related]
14. Beyond LDL-C--the importance of raising HDL-C. Wierzbicki AS; Mikhailidis DP Curr Med Res Opin; 2002; 18(1):36-44. PubMed ID: 11999145 [TBL] [Abstract][Full Text] [Related]
15. Optimal therapy of low levels of high density lipoprotein-cholesterol. Kashyap ML; Tavintharan S; Kamanna VS Am J Cardiovasc Drugs; 2003; 3(1):53-65. PubMed ID: 14727946 [TBL] [Abstract][Full Text] [Related]
16. Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment. Hersberger M; von Eckardstein A Drugs; 2003; 63(18):1907-45. PubMed ID: 12930163 [TBL] [Abstract][Full Text] [Related]
17. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol. Syvänne M; Nieminen MS; Frick MH; Kauma H; Majahalme S; Virtanen V; Kesäniemi YA; Pasternack A; Ehnholm C; Taskinen MR Circulation; 1998 Nov; 98(19):1993-9. PubMed ID: 9808595 [TBL] [Abstract][Full Text] [Related]
18. Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention? Rizos E; Mikhailidis DP Cardiovasc Res; 2001 Nov; 52(2):199-207. PubMed ID: 11684067 [TBL] [Abstract][Full Text] [Related]
19. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Evans M; Roberts A; Davies S; Rees A Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326 [TBL] [Abstract][Full Text] [Related]
20. The antiatherogenic role of high-density lipoprotein cholesterol. Kwiterovich PO Am J Cardiol; 1998 Nov; 82(9A):13Q-21Q. PubMed ID: 9819099 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]